Obchod Eli Lilly & Co - LLY CFD
Pridať medzi obľúbené- Zhrnutie
- Historické dáta
- Udalosti
- Výkaz ziskov a strát
- Súvahový list
- Peňažný tok
- Vlastníctvo
Rozpätie | 0.69 | ||||||||
Nočný poplatok dlhej pozície
Long position overnight fee
Prejsť na platformu | -0.030779% | ||||||||
Nočný poplatok krátkej pozície
Short position overnight fee
Prejsť na platformu | -0.013666% | ||||||||
Nočný poplatok | 22:00 (UTC) | ||||||||
Minimálne množstvo na obchodovanie | 1 | ||||||||
Mena | USD | ||||||||
Marža | 20% | ||||||||
Burza cenných papierov | United States of America | ||||||||
Provízia pri predaji | 0% |
*Information provided by Capital.com
Eli Lilly and Co ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Predchádzajúce Zavrieť* | 336.19 |
Otvoriť* | 334.39 |
1-ročná zmena* | 37.33% |
Denný rozsah* | 332.96 - 340.52 |
Rozsah 52 týždňov | 231.87-384.44 |
Priemerný objem (10 dní) | 3.95M |
Priemerný objem (3 mesiace) | 59.76M |
Trhová kapitalizácia | 320.84B |
Pomer P/E | 48.92 |
Zdieľa mimoriadne | 950.18M |
Výnosy | 28.54B |
EPS | 6.90 |
Dividenda (udalosť %) | 1.33862 |
Beta | 0.33 |
Ďalší dátum zárobku | Apr 27, 2023 |
Všetky údaje poskytuje spoločnosť Refinitiv, okrem údajov označených hviezdičkou, čo sú *údaje poskytnuté Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zatvorenie | Change | Change (%) | Otvorenie | High | Low |
---|---|---|---|---|---|---|
Feb 7, 2023 | 339.31 | 3.61 | 1.08% | 335.70 | 340.66 | 331.67 |
Feb 6, 2023 | 336.19 | -2.06 | -0.61% | 338.25 | 342.99 | 334.08 |
Feb 3, 2023 | 337.93 | 5.58 | 1.68% | 332.35 | 342.09 | 328.30 |
Feb 2, 2023 | 330.39 | -2.41 | -0.72% | 332.80 | 334.80 | 316.14 |
Feb 1, 2023 | 342.15 | 1.23 | 0.36% | 340.92 | 345.40 | 336.80 |
Jan 31, 2023 | 343.91 | 5.17 | 1.53% | 338.74 | 344.11 | 338.74 |
Jan 30, 2023 | 340.18 | -1.86 | -0.54% | 342.04 | 347.28 | 339.15 |
Jan 27, 2023 | 341.77 | -2.99 | -0.87% | 344.76 | 347.70 | 341.32 |
Jan 26, 2023 | 347.65 | -2.14 | -0.61% | 349.79 | 351.79 | 346.30 |
Jan 25, 2023 | 349.26 | 7.35 | 2.15% | 341.91 | 349.50 | 341.91 |
Jan 24, 2023 | 345.92 | -16.82 | -4.64% | 362.74 | 364.89 | 339.80 |
Jan 23, 2023 | 341.82 | -2.04 | -0.59% | 343.86 | 345.86 | 339.80 |
Jan 20, 2023 | 345.80 | 1.01 | 0.29% | 344.79 | 348.73 | 341.12 |
Jan 19, 2023 | 350.82 | 1.39 | 0.40% | 349.43 | 355.30 | 349.43 |
Jan 18, 2023 | 351.45 | -4.05 | -1.14% | 355.50 | 358.73 | 351.25 |
Jan 17, 2023 | 357.38 | -1.09 | -0.30% | 358.47 | 361.50 | 356.17 |
Jan 13, 2023 | 361.23 | 6.08 | 1.71% | 355.15 | 362.95 | 355.15 |
Jan 12, 2023 | 358.72 | 3.25 | 0.91% | 355.47 | 360.15 | 351.69 |
Jan 11, 2023 | 359.86 | 7.67 | 2.18% | 352.19 | 361.49 | 348.71 |
Jan 10, 2023 | 352.54 | 5.75 | 1.66% | 346.79 | 352.96 | 342.22 |
Eli Lilly & Co Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Výročný
- Štvrťročne
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Celkové príjmy | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Výnosy | 21222.1 | 19973.8 | 21493.3 | 22319.5 | 24539.8 | 28318.4 |
Náklady na výnosy, celkom | 5654.9 | 4447.7 | 4681.7 | 4721.2 | 5483.3 | 7312.8 |
Hrubý zisk | 15567.2 | 15526.1 | 16811.6 | 17598.3 | 19056.5 | 21005.6 |
Celkové prevádzkové náklady | 17763.3 | 17970.5 | 17958.8 | 17287.9 | 18481.8 | 22366.5 |
Predaj/Všeobecné/Správca. Náklady, Celkom | 6452 | 5982.4 | 5975.1 | 6213.8 | 6121.2 | 6431.6 |
Výskum a vývoj | 5243.9 | 5096.2 | 5051.2 | 5595 | 6085.7 | 7025.9 |
Nezvyčajné výdavky (príjem) | 412.5 | 2444.2 | 2250.8 | 757.9 | 791.6 | 1596.2 |
Prevádzkový príjem | 3458.8 | 2003.3 | 3534.5 | 5031.6 | 6058 | 5951.9 |
Úrokový príjem (výdavky), čistý neprevádzkový | -76.5 | -58.6 | -83.2 | -320.2 | -326.6 | -137.5 |
Iné, Net | -8.3 | 360.1 | 228.8 | 554.5 | 1498.5 | 341.1 |
Čistý príjem pred zdanením | 3374 | 2304.8 | 3680.1 | 5265.9 | 7229.9 | 6155.5 |
Čistý príjem po zdanení | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Čistý príjem pred extra. Položky | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Čistý príjem | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Príjem k dispozícii bežnému Extra. Položky | 2737.6 | 4493.6 | 3325.9 | 4637.9 | 6193.7 | 5581.7 |
Príjem k dispozícii bežnému vr. Extra. Položky | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Zriedený čistý príjem | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Zriedený vážený priemer akcií | 1061.82 | 1052.02 | 1033.67 | 935.684 | 912.505 | 911.681 |
Zriedený EPS s výnimkou mimoriadnych položiek | 2.5782 | 4.27139 | 3.21757 | 4.95669 | 6.78758 | 6.12243 |
Dividends per Share - Common Stock Primary Issue | 2.04 | 2.08 | 2.25 | 2.58 | 2.96 | 3.4 |
Zriedený normalizovaný EPS | 2.89874 | 6.15171 | 5.37021 | 5.70063 | 7.63447 | 7.79951 |
Celkom mimoriadne položky | -4697.7 | -93.9 | 3680.5 | 0 | 0 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Celkové príjmy | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Výnosy | 6805.6 | 6740.1 | 6772.8 | 7999.9 | 7810 |
Náklady na výnosy, celkom | 1878.6 | 1953.2 | 1430.8 | 2050.2 | 2072.1 |
Hrubý zisk | 4927 | 4786.9 | 5342 | 5949.7 | 5737.9 |
Celkové prevádzkové náklady | 5650.3 | 5336.7 | 5296.8 | 6082.7 | 5405.7 |
Predaj/Všeobecné/Správca. Náklady, Celkom | 1576 | 1685.7 | 1577.9 | 1592 | 1557.9 |
Výskum a vývoj | 1684.8 | 1672.8 | 1708.9 | 1959.4 | 1610.1 |
Nezvyčajné výdavky (príjem) | 510.9 | 25 | 579.2 | 481.1 | 165.6 |
Prevádzkový príjem | 1155.3 | 1403.4 | 1476 | 1917.2 | 2404.3 |
Úrokový príjem (výdavky), čistý neprevádzkový | 219.2 | 133.9 | -323.4 | -167.2 | -503.3 |
Iné, Net | 101.9 | 56.6 | 92.7 | 89.9 | 152.6 |
Čistý príjem pred zdanením | 1476.4 | 1593.9 | 1245.3 | 1839.9 | 2053.6 |
Čistý príjem po zdanení | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Čistý príjem pred extra. Položky | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Čistý príjem | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Príjem k dispozícii bežnému Extra. Položky | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Príjem k dispozícii bežnému vr. Extra. Položky | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Zriedený čistý príjem | 1355.3 | 1390.2 | 1110.1 | 1726.1 | 1902.9 |
Zriedený vážený priemer akcií | 912.4 | 910.4 | 910.8 | 911.624 | 906.4 |
Zriedený EPS s výnimkou mimoriadnych položiek | 1.48542 | 1.52702 | 1.21882 | 1.89343 | 2.0994 |
Dividends per Share - Common Stock Primary Issue | 0.85 | 0.85 | 0.85 | 0.85 | 0.98 |
Zriedený normalizovaný EPS | 2.02635 | 1.55448 | 1.80644 | 2.41408 | 2.28211 |
Celkom mimoriadne položky | 0 |
- Výročný
- Štvrťročne
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Celkové aktíva | 15101.4 | 19202.1 | 20549.6 | 13709.6 | 17462.1 | 18452.4 |
Hotovosť a krátkodobé investície | 6038.6 | 8034.1 | 7408.9 | 2438.5 | 3681.3 | 3908.6 |
Hotovosť a ekvivalenty | 4582.1 | 6536.2 | 7320.7 | 2337.5 | 3657.1 | 3818.5 |
Krátkodobé investície | 1456.5 | 1497.9 | 88.2 | 101 | 24.2 | 90.1 |
Pohľadávky celkom, netto | 4766.3 | 5262.2 | 5776.8 | 5541.5 | 6929 | 8127.2 |
Accounts Receivable - Trade, Net | 4029.4 | 4546.3 | 5776.8 | 4547.3 | 5875.3 | 6672.8 |
Total Inventory | 3561.9 | 4458.3 | 3098.1 | 3190.7 | 3980.3 | 3886 |
Prepaid Expenses | 734.6 | 1447.5 | 2036.7 | 2538.9 | 2871.5 | 2530.6 |
Total Assets | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Property/Plant/Equipment, Total - Net | 8252.6 | 8826.5 | 7996.1 | 8405 | 8681.9 | 8985.1 |
Property/Plant/Equipment, Total - Gross | 16777.6 | 18091.1 | 16663 | 17566.6 | 18252.6 | 18961.8 |
Accumulated Depreciation, Total | -8525 | -9264.6 | -8666.9 | -9161.6 | -9570.7 | -9976.7 |
Goodwill, Net | 3972.7 | 4370.1 | 1366.6 | 3679.4 | 3766.5 | 3892 |
Intangibles, Net | 4357.9 | 4029.2 | 1068 | 6618 | 7450 | 7691.9 |
Long Term Investments | 5207.5 | 5678.8 | 2005.4 | 1962.4 | 2966.8 | 3212.6 |
Other Long Term Assets, Total | 1913.8 | 2874.3 | 10922.7 | 4911.7 | 6305.8 | 6572 |
Total Current Liabilities | 10986.6 | 14535.9 | 11888.1 | 11775.2 | 12481.6 | 15052.7 |
Accounts Payable | 1349.3 | 1410.7 | 1207.1 | 1405.3 | 1606.7 | 1670.6 |
Accrued Expenses | 896.9 | 997.9 | 955.6 | 915.5 | 997.2 | 958.1 |
Notes Payable/Short Term Debt | 1299.3 | 2696.8 | 498.9 | 1494.2 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 638.1 | 1009.8 | 603.3 | 5.1 | 8.7 | 1538.3 |
Other Current Liabilities, Total | 6803 | 8420.7 | 8623.2 | 7955.1 | 9869 | 10885.7 |
Total Liabilities | 24798.2 | 33388.8 | 34079.7 | 36679.2 | 40991.5 | 39826.8 |
Total Long Term Debt | 8367.8 | 9940.5 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Long Term Debt | 8358.8 | 9931.8 | 9196.4 | 13817.9 | 16586.6 | 15346.4 |
Capital Lease Obligations | 9 | 8.7 | ||||
Minority Interest | 72.8 | 75.7 | 1080.4 | 92.2 | 183.6 | 175.6 |
Other Liabilities, Total | 5371 | 8836.7 | 10602.1 | 8806.4 | 9639.8 | 7518.4 |
Total Equity | 14007.7 | 11592.2 | 9828.7 | 2606.9 | 5641.6 | 8979.2 |
Common Stock | 688.5 | 687.9 | 661 | 598.8 | 598.2 | 596.3 |
Additional Paid-In Capital | 5640.6 | 5817.8 | 6583.6 | 6685.3 | 6778.5 | 6833.4 |
Retained Earnings (Accumulated Deficit) | 16046.3 | 13894.1 | 11395.9 | 4920.4 | 7830.2 | 8958.5 |
Treasury Stock - Common | -80.5 | -75.8 | -69.4 | -60.8 | -55.7 | -52.7 |
Unrealized Gain (Loss) | 224 | 113.5 | 4.9 | 14.8 | 3.7 | |
Other Equity, Total | -8511.2 | -8845.3 | -8742.4 | -9541.7 | -9524.4 | -7360 |
Total Liabilities & Shareholders’ Equity | 38805.9 | 44981 | 43908.4 | 39286.1 | 46633.1 | 48806 |
Total Common Shares Outstanding | 1100.88 | 1100.01 | 1057.64 | 957.526 | 956.59 | 953.653 |
Other Current Assets, Total | 2229.1 | 0 | ||||
Deferred Income Tax | 1312.7 | 2187.5 | 2099.9 | 1733.7 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Celkové aktíva | 16604.5 | 17295.5 | 17808.3 | 18452.4 | 16964.7 |
Hotovosť a krátkodobé investície | 3051.4 | 3271.2 | 3825.3 | 3908.6 | 2568.3 |
Hotovosť a ekvivalenty | 3002.4 | 3220 | 3788.2 | 3818.5 | 2459.2 |
Krátkodobé investície | 49 | 51.2 | 37.1 | 90.1 | 109.1 |
Pohľadávky celkom, netto | 6658.6 | 6902.8 | 7025 | 8127.2 | 7805.7 |
Accounts Receivable - Trade, Net | 5592.8 | 5829.4 | 5914.3 | 6672.8 | 6322.5 |
Total Inventory | 3660.8 | 3824.9 | 3907.4 | 3886 | 3893 |
Prepaid Expenses | 3233.7 | 3296.6 | 3050.6 | 2530.6 | 2697.7 |
Total Assets | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Property/Plant/Equipment, Total - Net | 8630.1 | 8855.5 | 8920.4 | 8985.1 | 9102.7 |
Property/Plant/Equipment, Total - Gross | 18273.5 | 18697.7 | 18883.2 | 18961.8 | 19241 |
Accumulated Depreciation, Total | -9643.4 | -9842.2 | -9962.8 | -9976.7 | -10138.3 |
Goodwill, Net | 3877.4 | 3884.2 | 3884.1 | 3892 | 3892 |
Intangibles, Net | 8087.8 | 7985.4 | 7887.7 | 7691.9 | 7482.4 |
Long Term Investments | 3232.4 | 3474.9 | 3350.5 | 3212.6 | 2727.3 |
Other Long Term Assets, Total | 6406.1 | 6313.5 | 6336 | 6572 | 6750.2 |
Total Current Liabilities | 11714.2 | 15093.2 | 13682 | 15052.7 | 13386 |
Accounts Payable | 1639.6 | 1597.8 | 1566.8 | 1670.6 | 1433.3 |
Accrued Expenses | 649.9 | 755.5 | 836.6 | 958.1 | 693.1 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 4.9 | 1778.5 | 1563 | 1538.3 | 1355.9 |
Other Current Liabilities, Total | 9419.8 | 10961.4 | 9715.6 | 10885.7 | 9903.7 |
Total Liabilities | 39939.6 | 41364.6 | 40430 | 39826.8 | 37588.5 |
Total Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Long Term Debt | 16199.6 | 14736.6 | 15522.4 | 15346.4 | 15152.9 |
Deferred Income Tax | 2200.6 | 1857.3 | 1632.5 | 1733.7 | 1286.1 |
Minority Interest | 200.6 | 219.1 | 197.1 | 175.6 | 131.2 |
Other Liabilities, Total | 9624.6 | 9458.4 | 9396 | 7518.4 | 7632.3 |
Total Equity | 6898.7 | 6444.4 | 7757 | 8979.2 | 9330.8 |
Common Stock | 599.7 | 598.1 | 598.2 | 596.3 | 594.1 |
Additional Paid-In Capital | 6579.2 | 6669.2 | 6758 | 6833.4 | 6656.3 |
Retained Earnings (Accumulated Deficit) | 9181.3 | 8530.1 | 9639.4 | 8958.5 | 9369.4 |
Treasury Stock - Common | -52.7 | -52.7 | -52.7 | -52.7 | -50.5 |
Unrealized Gain (Loss) | 4.5 | 9.1 | 6.8 | 3.7 | -18.1 |
Other Equity, Total | -9413.3 | -9309.4 | -9192.7 | -7360 | -7220.4 |
Total Liabilities & Shareholders’ Equity | 46838.3 | 47809 | 48187 | 48806 | 46919.3 |
Total Common Shares Outstanding | 959.019 | 956.575 | 956.589 | 953.653 | 950.155 |
- Výročný
- Štvrťročne
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Čistý príjem/Počiatočná čiara | 2737.6 | -204.1 | 3232 | 8318.4 | 6193.7 | 5581.7 |
Hotovosť z prevádzkovej činnosti | 4851 | 5615.6 | 5524.5 | 4836.6 | 6499.6 | 7260.7 |
Hotovosť z prevádzkovej činnosti | 1496.6 | 1567.3 | 1609 | 1232.6 | 1323.9 | 1547.6 |
Deferred Taxes | 439.5 | -787.9 | 326.8 | 62.4 | -134.5 | -802.3 |
Bezhotovostné položky | 661.4 | 1835.4 | 2735.4 | -3089.6 | -136.1 | 1956.3 |
Cash Taxes Paid | 700.6 | 246.5 | 1101.5 | 1180.5 | 954.6 | 1598.8 |
Úroky zaplatené v hotovosti | 146.4 | 192.7 | 223.8 | 305.5 | 345.8 | 338 |
Zmeny pracovného kapitálu | -484.1 | 3204.9 | -2378.7 | -1687.2 | -747.4 | -1022.6 |
Peniaze z investičných činností | -3139.1 | -3783.6 | 1906 | -8082.9 | -2258.9 | -2762.3 |
Kapitálové výdavky | -1092 | -2163.6 | -3018.2 | -1353.5 | -2029.1 | -1873.2 |
Ostatné investičné položky peňažných tokov, celkom | -2047.1 | -1620 | 4924.2 | -6729.4 | -229.8 | -889.1 |
Hotovosť z finančných činností | -559.8 | 142.6 | -5904.9 | -2324.5 | -3137.1 | -4131.3 |
Financovanie položiek peňažných tokov | -300.8 | -364.4 | -372.8 | -200.1 | -241.6 | -295.9 |
Total Cash Dividends Paid | -2158.5 | -2192.1 | -2311.8 | -2409.8 | -2687.1 | -3086.8 |
Vydanie (vyradenie) zásob, netto | -600.1 | -299.8 | -2491 | -4400 | -500 | -1250 |
Vydanie (vyradenie) dlhu, netto | 2499.6 | 2998.9 | -729.3 | 4685.4 | 291.6 | 501.4 |
Devízové efekty | -236.4 | -20.5 | -63.6 | -89.9 | 216 | -205.7 |
Čistá zmena v hotovosti | 915.7 | 1954.1 | 1462 | -5660.7 | 1319.6 | 161.4 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1355.3 | 2745.5 | 3855.6 | 5581.7 | 1902.9 |
Cash From Operating Activities | 1697.4 | 3472.9 | 5104.2 | 7260.7 | 2499.2 |
Cash From Operating Activities | 350.3 | 719.6 | 1101.9 | 1547.6 | 435.7 |
Deferred Taxes | -119.1 | -413.8 | -709.8 | -802.3 | -506.6 |
Non-Cash Items | 213.7 | 303.2 | 1404.6 | 1956.3 | 712.7 |
Changes in Working Capital | -102.8 | 118.4 | -548.1 | -1022.6 | -45.5 |
Cash From Investing Activities | -1283.5 | -1766.8 | -2383.3 | -2762.3 | -1013.8 |
Capital Expenditures | -492.1 | -1023.4 | -1479 | -1873.2 | -857.2 |
Other Investing Cash Flow Items, Total | -791.4 | -743.4 | -904.3 | -889.1 | -156.6 |
Cash From Financing Activities | -1058.4 | -2141.6 | -2604.8 | -4131.3 | -2878.3 |
Financing Cash Flow Items | -279.9 | -294.8 | -295.3 | -295.9 | -282.4 |
Total Cash Dividends Paid | -774.8 | -1543.1 | -2313.5 | -3086.8 | -885.5 |
Issuance (Retirement) of Stock, Net | 0 | -500 | -500 | -1250 | -1500 |
Issuance (Retirement) of Debt, Net | -3.7 | 196.3 | 504 | 501.4 | -210.4 |
Foreign Exchange Effects | -10.2 | -1.6 | 15 | -205.7 | 33.6 |
Net Change in Cash | -654.7 | -437.1 | 131.1 | 161.4 | -1359.3 |
Meno investora | Typ investora | Percento vynikajúce | Držané akcie | Zmena akcií | Dátum držby | Hodnotenie obratu |
---|---|---|---|---|---|---|
Lilly Endowment, Inc. | Investment Advisor | 10.8347 | 102948810 | -210000 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.6008 | 72221213 | 994066 | 2022-09-30 | LOW |
PNC Wealth Management | Investment Advisor | 5.4451 | 51738161 | -44061 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2364 | 40253792 | 58949 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.5343 | 33582472 | 168444 | 2022-09-30 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.3604 | 31929656 | 631015 | 2022-09-30 | LOW |
Capital World Investors | Investment Advisor | 3.0547 | 29024874 | 282228 | 2022-09-30 | LOW |
PRIMECAP Management Company | Investment Advisor | 2.9486 | 28017155 | -421333 | 2022-09-30 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.5054 | 23805927 | 3379269 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.2989 | 21843288 | -1593968 | 2022-09-30 | LOW |
State Farm Insurance Companies | Insurance Company | 1.8324 | 17410725 | 0 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.6935 | 16091249 | 373938 | 2022-09-30 | LOW |
Jennison Associates LLC | Investment Advisor/Hedge Fund | 1.0592 | 10064742 | -293324 | 2022-09-30 | LOW |
JP Morgan Asset Management | Investment Advisor | 0.866 | 8228610 | 173535 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8435 | 8014500 | -246196 | 2021-12-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.7439 | 7068030 | -132558 | 2022-09-30 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.6244 | 5933104 | -307204 | 2022-09-30 | LOW |
Capital International Investors | Investment Advisor | 0.5893 | 5599174 | 637189 | 2022-09-30 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 0.5885 | 5591703 | -216451 | 2022-09-30 | LOW |
BofA Global Research (US) | Research Firm | 0.5868 | 5576096 | -144521 | 2022-09-30 | LOW |
Prečo si vybrať Capital.com? Naše čísla hovoria samy za seba.
Capital.com GroupObchodníci
Aktívni klienti za mesia
Mesačný objem investícií
Výbery každý mesiac
Obchodná kalkulačka
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Eli Lilly Company profile
O spoločnosti Eli Lilly & Co
Eli Lilly and Company je spoločnosť vyrábajúca lieky. Spoločnosť sa zaoberá objavovaním, vývojom, výrobou, marketingom a predajom farmaceutických výrobkov na celom svete. Medzi produkty spoločnosti na liečbu cukrovky patria Baqsimi, Basaglar, Humalog, Humulin, Jardiance, Lyumjev, Trajenta a Trulicity. Medzi jej onkologické výrobky patria Alimta, Cyramza, Erbitux, Retevmo, Tyvyt a Verzenio. Imunologické produkty spoločnosti pozostávajú z liekov Olumiant a Taltz. Medzi jej neurovedecké produkty patria Cymbalta, Emgality, Reyvow a Zyprexa. Ďalšie liečebné prípravky spoločnosti tvoria Bamlanivimab, etesevimab, Cialis a Forteo. Spoločnosť vyrába a distribuuje svoje produkty prostredníctvom zariadení v Spojených štátoch vrátane Portorika a približne v ôsmich ďalších krajinách. Jej výrobky sa predávajú v približne 120 krajinách. Medzi jej dcérske spoločnosti patria okrem iného Acanthas Pharma, Inc, Alnara Pharmaceuticals, Inc, ARMO Biosciences, Inc a Avid Radiopharmaceuticals, Inc.
Industry: | Pharmaceuticals (NEC) |
Lilly Corporate Ctr
Drop Code 1094
INDIANAPOLIS
INDIANA 46285-0001
US
Výkaz ziskov a strát
- Annual
- Quarterly
Ľudia tiež sledujú
Stále hľadáte brokera, ktorému sa dá veriť?
Pridajte sa k 500 000 obchodníkom na celom svete, ktorí sa rozhodli obchodovať s Capital.com